The IRF family of transcription factors inception, impact and implications in oncogenesis

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1376-1386

  Yanai, Hideyuki ^a,b   Negishi, Hideo ^a,b   Taniguchi, Tadatsugu ^a,b  

^a INSTITUTE OF INDUSTRIAL SCIENCE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Cancer; Cytokine; Interferon regulatory factor; Oncogenesis; Transcriptional regulation

Indexed keywords

CYCLIN DEPENDENT KINASE; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 4; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 6; INTERFERON REGULATORY FACTOR 7; INTERFERON REGULATORY FACTOR 9;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; BIOGENESIS; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CROSS HYBRIDIZATION; DENDRITIC CELL; DNA DAMAGE; FIBROBLAST; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRANSGENE; TUMOR IMMUNITY; UBIQUITINATION;

EID: 84877656613     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22475     Document Type: Review

References (139)

1. Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, et al. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-β gene regulatory elements. Cell 1988; 54:903-13; PMID:3409321; http://dx.doi.org/10.1016/S0092-8674(88)91307-4.
2. Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, et al. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 1989; 58:729-39; PMID:2475256; http://dx.doi.org/10.1016/0092-8674(89)90107-4.
3. Driggers PH, Ennist DL, Gleason SL, Mak WH, Marks MS, Levi BZ, et al. An interferon gammaregulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A 1990; 87:3743-7; PMID:2111015; http://dxldoi.org/10.1073/pnas.87.10.3743.
4. Eisenbeis CF, Singh H, Storb U. Pip, a novel IRF family member, is a lymhoid-specific, PU.1-dependent transcriptional activator. Genes Dev 1995; 9:1377-87; PMID:7797077; http://dx.doi.org/10.1101/gad.9.11.1377.
5. Levy DE, Kessler DS, Pine R, Darnell JE Jr. Cytoplasmic activation of ISGF3, the positive regulator of interferon-a-stimulated transcription, reconstituted in vitro. Genes Dev 1989; 3:1362-71; PMID:2606351; http://dx.doi.org/10.1101/gad.3.9.1362.
6. Matsuyama T, Grossman A, Mittrücker HW, Siderovski DP, Kiefer F, Kawakami T, et al. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferonstimulated response element (ISRE). Nucleic Acids Res 1995; 23:2127-36; PMID:7541907; http://dxldoi.org/10.1093/nar/23.12.2127.
7. Weisz A, Marx P, Sharf R, Appella E, Driggers PH, Ozato K, et al. Humaninterferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. J Biol Chem 1992; 267:25589-96; PMID:1460054.
8. Yamagata T, Nishida J, Tanaka S, Sakai R, Mitani K, Yoshida M, et al. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferonregulated genes. Mol Cell Biol 1996; 16:1283-94; PMID:8657101.
9. Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996; 274:1739-44; PMID:8939871; http://dxldoi.org/10.1126/science.274.5293.1739.
10. Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, et a. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A 1996; 93:14862-7; PMID:8962146; http://dx.doi.org/10.1073/pnas.93.25.14862.
11. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008; 26:535-84; PMID:18303999; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090400.
12. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001; 19:623-55; PMID:11244049; http://dxldoi.org/10.1146/annurev.immunol.19.1.623.
13. Darnell JE Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activaton in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415-21; PMID:8197455; http://dx.doi.org/10.1126/science.8197455.
14. Fujii Y, Shimizu T, Kusumoto M, Kyogoku Y, Taniguchi T, Hakoshima T. Crystal structure of an IRF-DNA complex reveals novel DNA recognition and cooperative binding to a tandem repeat of core sequences. EMBO J 1999; 18:5028-41; PMID:10487755; http://dx.doi.org/10.1093/emboj/18.18.5028.
15. Meraro D, Hashmueli S, Koren B, Azriel A, Oumard A, Kirchhoff S, et al. Protein-protein and DNA-protein interactions affect the activity of lymphoid-specific IFN regulatory factors. J Immunol 1999; 163:6468-78; PMID:10586038.
16. Mamane Y, Heylbroeck C, GéninP, Algarté M, Servant MJ, LePage C, et al. Interferon regulatory factors: the next generation. Gene 1999; 237:1-14; PMID:10524230; http://dx.doi.org/10.1016/S0378-1119(99)00262-0.
17. Colonna M. TLR pathways and IFN-regulatory factors: to each its own. Eur J Immunol 2007; 37:306-9; PMID:17273997; http://dx.doi.org/10.1002/eji.200637009.
18. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006; 6:644-58; PMID:16932750; http://dxldoi.org/10.1038/nri1900.
19. Nguyen H, Hiscott J, Pitha PM. The growing family of interfern regulatory factors. Cytokine Growth Factor Rev 1997; 8:293-312; PMID:9620643; http://dx.doi.org/10.1016/S1359-6101(97)00019-1.
20. Ozato K, Tailor P, Kubota T. The interferon regulatory factor family in host defense: mechanism of action. J Biol Chem 2007; 282:20065-9; PMID:17502370; http://dx.doi.org/10.1074/jbc.R700003200.
21. Paun A, Pitha PM. The IRF family, revisited. Biochimie 2007; 89:744-53; PMID:17399883; http://dxldoi.org/10.1016/j.biochi.2007.01.014.
22. Savitsky D, Tamura T, Yanai H, Taniguchi T. Regulation of immunity and oncognesis by the IRF transcription factor family. Cancer Immunol Immunother 2010; 59:489-510; PMID:20049431; http://dx.doi.org/10.1007/s00262-009-0804-6.
23. Takaoka A, Tamura T, Taniguchi T. Interferon regulatory factor family of transcription factors and regulation of oncogenesis. Cancer Sci 2008; 99:467-78; PMID:18190617; http://dx.doi.org/10.1111/j.1349-7006.2007.00720.x.
24. Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M, et al. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993; 259:971-4; PMID:8438157; http://dxldoi.org/10.1126/science.8438157.
25. Tanaka N, Ishihara M, Lamphier MS, Nozawa H, Matsuyama T, Mak TW, et a. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature 1996; 382:816-8; PMID:8752276; http://dx.doi.org/10.1038/382816a0.
26. Pamment J, Ramsay E, Kelleher M, Dornan D, Ball KL. Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway. Oncogene 2002; 21:7776-85; PMID:12420214; http://dx.doi.org/10.1038/sj.onc.1205981.
27. Frontini M, Vijayakumar M, Garvin A, Clarke N. A ChIP-chip approach reveals a novel role for transcription factor IRF1 in the DNA damage response. Nucleic Acids Res 2009; 37:1073-85; PMID:19129219; http://dxldoi.org/10.1093/nar/gkn1051.
28. Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, e al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994; 77:829-39; PMID:8004672; http://dx.doi.org/10.1016/0092-8674(94)90132-5.
29. Tamura T, Ishihara M, Lamphier MS, Tanaka N, Oishi I, Aizawa S, et al. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 1995; 376:596-9; PMID:7637809; http://dx.doi.org/10.1038/376596a0.
30. Lallemand C, Palmieri M, Blanchard B, Meritet JF, Tovey MG. GAAP-1: a transcriptional activator of p53 and IRF-1 possesses pro-apoptotic activity. EMBO Rep 2002; 3:153-8; PMID:11818340; http://dxldoi.org/10.1093/embo-reports/kvf032.
31. Kano A, Haruyama T, Akaike T, Watanabe Y. IRF-1 is an essential mediator n IFN-γ-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. Biochem Biophys Res Commun 1999; 257:672-7; PMID:10208842; http://dx.doi.org/10.1006/bbrc.1999.0276.
32. Kim EJ, Lee JM, Namkoong SE, Um SJ, Park JS. Interferon regulatory factor-1 mediates interferongamma-induced apoptosis in ovarian carcinoma cells. J Cell Biochem 2002; 85:369-80; PMID:11948692; http://dx.doi.org/10.1002/jcb.10142.
33. Tomita Y, Bilim V, Hara N, Kasahara T, Takahashi K. Role of IRF-1 and caspase-7 in IFN-γ enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. Int J Cancer 2003; 104:400-8; PMID:12584735; http://dxldoi.org/10.1002/ijc.10956.
34. Tan RS, Taniguchi T, Harada H. Identification of the lysyl oxidae gene as target of the antioncogenic transcription factor, IRF-1, and its possible role in tumor suppression. Cancer Res 1996; 56:2417-21; PMID:8625321.
35. Jeay S, Pianetti S, Kagan HM, Sonenshein GE. Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-κB B. Mol Cell Biol 2003; 23:2251-63; PMID:12640111; http://dx.doi.org/10.1128/MCB.23.7.2251-2263.2003.
36. Passioura T, Dolnikov A, Shen S, Symonds G. N-ras-induced growth suppression of myeloid cells is mediated by IRF-1. Cancer Res 2005; 65:797-804; PMID:15705876.
37. Tanaka N, Ishihara M, Taniguhi T. Suppression of c-myc or fosB-induced cell transformation by the transcription factor IRF-1. Cancer Lett 1994; 83:191-6; PMID:8062214; http://dx.doi.org/10.1016/0304-3835(94)90318-2.
38. Nozawa H, Oda E, Nakao K, Ishihara M, Ueda S, Yokochi T, et al. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev 1999; 13:1240-5; PMID:10346812; http://dx.doi.org/10.1101/gad.13.10.1240.
39. Park J, Kim K, Lee EJ, Seo YJ, Lim SN, Park K, et al. Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis. Proc Natl Acad Sci U S A 2007; 104:17028-33; PMID:17942705; http://dxldoi.org/10.1073/pnas.0609852104.
40. Harada H, Kondo T, Ogawa S, Tamura T, Kitagawa M, Tanaka N, et al. Acceleraed exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene 1994; 9:3313-20; PMID:7936656.
41. Tzoanopoulos D, Speletas M, Arvanitidis K, Veiopoulou C, Kyriaki S, Thyphronitis G, et al. Low expression of interferon regulatory factor-1 and identification of novel exons skipping in patients with chronic myeloid leukaemia. Br J Haematol 2002; 119:46-53; PMID:12358902; http://dx.doi.org/10.1046/j.1365-2141.2002.03829.x.
42. Kondo T, Minamino N, Nagamura-Inoue T, Matsumoto M, Taniguchi T, Tanaka N. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene 1997; 15:1275-81; PMID:9315094; http://dxldoi.org/10.1038/sj.onc.1201286.
43. Narayan V, Halada P, Hernychová L, Chong YP, Žáková J, Hupp TR, et al.A multiprotein binding interface in an intrinsically disordered region of the tumor suppressor protein interferon regulatory factor-1. J Biol Chem 2011; 286:14291-303; PMID:21245151; http://dx.doi.org/10.1074/jbc.M110.204602.
44. Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML, et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993; 259:968-71; PMID:8438156; http://dx.doi.org/10.1126/science.8438156.
45. Ogasawara S, Tamura G, Maesawa C, Suzuki Y, Ishida K, Satoh N, et al. Common deleted region on the long arm of chromosome 5 in esophageal carcinoma. Gastroenterology 1996; 110:52-7; PMID:8536888; http://dxldoi.org/10.1053/gast.1996.v110.pm8536888.
46. Tamura G, Ogasawara S, Nishizuka S, Sakata K, Maesawa C, Suzuki Y, et al. Two istinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. Cancer Res 1996; 56:612-5; PMID:8564980.
47. Nozawa H, Oda E, Ueda S, Tamura G, Maesawa C, Muto T, et al. Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer. Int J Cancer 1998; 77:522-7; PMID:9679752; http://dx.doi.org/10.1002/(SICI)1097-0215(19980812)77:4<522::AIDIJC8> 3.0.CO;2-W.
48. Tirkknen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 1998; 21:177-84; PMID:9523192; http://dx.doi.org/10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.0.CO;2-X.
49. Doherty GM, Boucher L, Sorenson K, Lowney J. Interferon regulatory factor expression in human breast cancer. Ann Surg 2001; 233:623-9; PMID:11323500; http://dx.doi.org/10.1097/00000658-200105000-00005.
50. Cavalli LR, Riggins RB, Wang A, Clarke R, Haddad BR. Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer. Breast Cancer Res Treat 2010; 121:227-31; PMID:19697121; http://dxldoi.org/10.1007/s10549-009-0509-8.
51. Cui L, Deng Y, Rong Y, Lou W, Mao Z, Feng Y, et al. IRF-2 is over-expressd in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol 2012; 33:247-55; PMID:22119988; http://dx.doi.org/10.1007/s13277-011-0273-3.
52. Passioura T, Shen S, Symonds G, Dolnikov A. A retroviral library genetic screen identifies IRF-2 as an inhibitor of N-ras-induced growth suppression in leukemic cells. Oncogene 2005; 24:7327-36; PMID:16007130; http://dx.doi.org/10.1038/sj.onc.1208877.
53. Nguyen H, Mustafa A, Hiscott J, Lin R. Transcription factor IRF-2 exerts its oncogenic phenoType through the DNA binding/transcription repression domain. Oncogene 1995; 11:537-44; PMID:7630638.
54. Yamamoto H, Lamphier MS, Fjita T, Taniguchi T, Harada H. The oncogenic transcription factor IRF-2 possesses a transcriptional repression and a latent activation domain. Oncogene 1994; 9:1423-8; PMID:8152803.
55. Vaughan PS, Aziz F, van Wijnen AJ, Wu S, Harada H, Taniguchi T, et al. Activation of a cell-cycle-regulated histone gene by the oncogenic transcription factor IRF-2. Nature 1995; 377:362-5; PMID:7566094; http://dx.doi.org/10.1038/377362a0.
56. Vaughan PS, van der Meijden CM, Aziz F, Harada H, Taniguchi T, van Wijnen AJ, et al. Cell cycle regulation of histone H4 gene transcription requires the oncogenic factor IRF-2. J Biol Chem 1998; 273:194-9; PMID:9417064; http://dxldoi.org/10.1074/jbc.273.1.194.
57. Masumi A, Yamakawa Y, Fukazawa H, Ozato K, Komuro K. Interferon regultory factor-2 regulates cell growth through its acetylation. J Biol Chem 2003; 278:25401-7; PMID:12738767; http://dx.doi.org/10.1074/jbc.M213037200.
58. Pettersson S, Kelleher M, Pion E, Wallace M, Ball KL. Role of Mdm2 acid domain interactions in recognition and ubiquitination of the transcription factor IRF-2. Biochem J 2009; 418:575-85; PMID:19032150; http://dx.doi.org/10.1042/BJ20082087.
59. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44:694-8; PMID:22561517; http://dxldoi.org/10.1038/ng.2256.
60. Sato M, Suemori H, Hata N, Asagiri M, Ogasawara K, Nakao K, etal. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-a/β gene induction. Immunity 2000; 13:539-48; PMID:11070172; http://dx.doi.org/10.1016/S1074-7613(00)00053-4.
61. Oshita F, Sekiyama A, Ito H, Kameda Y, Miyagi Y. Genome-wide cDNA microarray screening of genes related to survival in patients after curative resection of non-small cell lung cancer. Oncol Rep 2006; 16:817-21; PMID:16969500.
62. Tokunaga T, Naruke Y, Shigematsu S, Kohno T, Yasui K, Ma Y, et al. Aberrant expression of interferon regulatory factor 3 in human lung cancer. Biochem Biophys Res Commun 2010;397:202-7; PMID:20501320; http://dxldoi.org/10.1016/j.bbrc.2010.05.085.
63. Heylbroeck C, Balachandran S, Servant MJ, DeLuca C, Barber GN, Lin R, et al. The IRF-3 transcription factor mediates Sendai virus-induced apoptosis. J Virol 2000; 74:3781-92; PMID:10729153; http://dx.doi.org/10.1128/JVI.74.8.3781-3792.2000.
64. Weaver BK, Ando O, Kumar KP, Reich NC. Apoptosis is promoted by the dsRNA-activated factor (DRAF1) during viral infection independent of the action of interferon or p53. FASEB J 2001; 15:501-15; PMID:11156966; http://dx.doi.org/10.1096/fj.00-0222com.
65. Kirshner JR, Karpova AY, Kops M, Howley PM. Identification of TRAIL as an interferon regulatory factor 3 transcriptional target. J Virol 2005; 79:9320-4; PMID:15994827; http://dxldoi.org/10.1128/JVI.79.14.9320-9324.2005.
66. Yanai H, Chen HM, Inuzuka T, Kondo S, Mak TW, Takaoka A, et al. Role of IFN regultory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc Natl Acad Sci U S A 2007; 104:3402-7; PMID:17360658; http://dx.doi.org/10.1073/pnas.0611559104.
67. Hsu LC, Park JM, Zhang K, Luo JL, Maeda S, Kaufman RJ, et al. The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 2004; 428:341-5; PMID:15029200; http://dx.doi.org/10.1038/nature02405.
68. Kim T, Kim TY, Song YH, Min IM, Yim J, Kim TK. Activation of interferon regulatory factor 3 in response to DNA-damaging agents. J Biol Chem 1999; 274:30686-9; PMID:10521456; http://dxldoi.org/10.1074/jbc.274.43.30686.
69. Karpova AY, Trost M, Murray JM, Cantley LC, Howley PM. Interferon regulatoy factor-3 is an in vivo target of DNA-PK. Proc Natl Acad Sci U S A 2002; 99:2818-23; PMID:11867762; http://dx.doi.org/10.1073/pnas.052713899.
70. Duguay D, Mercier F, Stagg J, Martineau D, Bramson J, Servant M, et al. In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. Cancer Res 2002; 62:5148-52; PMID:12234977.
71. Kim TY, Lee KH, Chang S, Chung C, Lee HW, Yim J, et al. Oncogenic potential of a dominant negative mutant of interferon regulatory factor 3. J Biol Chem 2003; 278:15272-8; PMID:12582166; http://dxldoi.org/10.1074/jbc.M205792200.
72. Shaffer AL, Emre NC, Romesser PB, Staudt LM. IRF4: Immunity Malignancy! Therapyχ Clin Cancer Res 2009; 15:2954-61; PMID:19383829; http://dx.doi.org/10.1158/1078-0432.CCR-08-1845.
73. Mamane Y, Grandvaux N, Hernandez E, Sharma S, Innocente SA, Lee JM, et al. Repression of IRF-4 target genes in human T cell leukemia virus-1 infection. Oncogene 2002; 21:6751-65; PMID:12360402; http://dx.doi.org/10.1038/sj.onc.1205843.
74. Mamane Y, Loignon M, Palmer J, Hernandez E, Césaire R, Alaoui-Jamali M, et al. Repression of DNA repair mechanisms in IRF-4-expressing and HTLV-I-infected T lymphocytes. J Interferon Cytokine Res 2005; 25:43-51; PMID:15684621; http://dxldoi.org/10.1089/jir.2005.25.43.
75. Feldman AL, Law M, Remstein ED, Macon WR, Erickson LA, Grogg KL, et a. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia 2009; 23:574-80; PMID:18987657; http://dx.doi.org/10.1038/leu.2008.320.
76. Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997; 17:226-30; PMID:9326949; http://dx.doi.org/10.1038/ng1097-226.
77. Heintel D, Zojer N, Schreder M, Strasser-Weippl K, Kainz B, Vesely M, et al. Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia 2008; 22:441-5; PMID:17690696; http://dxldoi.org/10.1038/sj.leu.2404895.
78. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, et al. IRF4 addction in multiple myeloma. Nature 2008; 454:226-31; PMID:18568025; http://dx.doi.org/10.1038/nature07064.
79. Saito T, Yamagata T, Takahashi T, Honda H, Hirai H. ICSAT overexpression is not sufficient to cause adult T-cell leukemia or multiple myeloma. Biochem Biophys Res Commun 1999; 260:329-31; PMID:10403770; http://dx.doi.org/10.1006/bbrc.1999.0911.
80. Yang Y, Shaffer AL 3rd, Emre NC, Ceribelli M, Zhang M, Wright G, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012; 21:723-37; PMID:22698399; http://dxldoi.org/10.1016/j.ccr.2012.05.024.
81. Pathak S, Ma S, Trinh L, Eudy J, Wagner KU, Joshi SS, et al. IRF4 is a sppressor of c-Myc induced B cell leukemia. PLoS One 2011; 6:e22628; PMID:21818355; http://dx.doi.org/10.1371/journal.pone.0022628.
82. Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res 2003; 63:6424-31; PMID:14559832.
83. Bi X, Hameed M, Mirani N, Pimenta EM, Anari J, Barnes BJ. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res 2011; 13:R111; PMID:22053985; http://dxldoi.org/10.1186/bcr3053.
84. Yang L, Zhao T, Shi X, Nakhaei P, Wang Y, Sun Q, et l. Functional analysis of a dominant negative mutation of interferon regulatory factor 5. PLoS One 2009; 4:e5500; PMID:19430534; http://dx.doi.org/10.1371/journal.pone.0005500.
85. Mori T, Anazawa Y, Iiizumi M, Fukuda S, Nakamura Y, Arakawa H. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene 2002; 21:2914-8; PMID:11973653; http://dx.doi.org/10.1038/sj.onc.1205459.
86. Hu G, Mancl ME, Barnes BJ. Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. Cancer Res 2005; 65:7403-12; PMID:16103093; http://dxldoi.org/10.1158/0008-5472.CAN-05-0583.
87. Couzinet A, Tamura K, Chen HM, Nishimura K, Wang Z, Morishita Y, et al. A cel-Type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis. Proc Natl Acad Sci U S A 2008; 105:2556-61; PMID:18268344; http://dx.doi.org/10.1073/pnas.0712295105.
88. Kondo S, Schutte BC, Richardson RJ, Bjork BC, Knight AS, Watanabe Y, et al. Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes. Nat Genet 2002; 32:285-9; PMID:12219090; http://dx.doi.org/10.1038/ng985.
89. Ingraham CR, Kinoshita A, Kondo S, Yang B, Sajan S, Trout KJ, et al. Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6). Nat Genet 2006; 38:1335-40; PMID:17041601; http://dxldoi.org/10.1038/ng1903.
90. Richardson RJ, Dixon J, Malhotra S, Hardman MJ, Knowles L, Boot-Handford RP, et al. Irf6 is a key determinant of the keratinocyte proliferation-differentiation switch. Nat Genet 2006; 38:1329-34; PMID:17041603; http://dx.doi.org/10.1038/ng1894.
91. Moretti F, Marinari B, Lo Iacono N, Botti E, Giunta A, Spallone G, et al. A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias. J Clin Invest 2010; 120:1570-7; PMID:20424325; http://dxldoi.org/10.1172/JCI40267.
92. Restivo G, Nguyen BC, Dziunycz P, Ristorcelli E, Ryan RJ, ÖzuysalOY, et al. IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes. EMBO J 2011; 30:4571-85; PMID:21909072; http://dx.doi.org/10.1038/emboj.2011.325.
93. Bailey CM, Hendrix MJ. IRF6 in development and disease: a mediator of quiescence and differentiation. Cell Cycle 2008; 7:1925-30; PMID:18604160; http://dx.doi.org/10.4161/cc.7.13.6221.
94. Bailey CM, Abbott DE, Margaryan NV, Khalkhali-Ellis Z, Hendrix MJ. Interferon regulatory factor 6 promotes cell cycle arrest and is regulated by the proteasome in a cell cycle-dependent manner. Mol Cell Biol 2008; 28:2235-43; PMID:18212048; http://dxldoi.org/10.1128/MCB.01866-07.
95. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IR-7 is the master regulator of Type-I interferon-dependent immune responses. Nature 2005; 434:772-7; PMID:15800576; http://dx.doi.org/10.1038/nature03464.
96. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 2012; In Press; PMID:22820642; http://dx.doi.org/10.1038/nm.2830.
97. Li Q, Tainsky MA. Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses. PLoS One 2011; 6:e28683; PMID:22194884; http://dxldoi.org/10.1371/journal.pone.0028683.
98. Holtschke T, Löhler J, Kanno Y, Fehr T, Giese N, Rosenbauer F, et al. Immundeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996; 87:307-17; PMID:8861914; http://dx.doi.org/10.1016/S0092-8674(00)81348-3.
99. Burchert A, Cai D, Hofbauer LC, Samuelsson MK, Slater EP, Duyster J, et al. Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood 2004; 103:3480-9; PMID:14656881; http://dx.doi.org/10.1182/blood-2003-08-2970.
100. Dror N, Rave-Harel N, Burchert A, Azriel A, Tamura T, Tailor P, et al. Interferon regulatory factor-8 is indispensable for the expression of promyelocytic leukemia and the formation of nuclear bodies in myeloid cells. J Biol Chem 2007; 282;5633-40;PMID: 17189268 http://dxldoi.org/10.1074/jbc.M607825200.
101. Tamura T, Kong HJ, Tunyaplin C, Tsujimura H, Calame K, Ozato K. ICSBP/RF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells. Blood 2003; 102:4547-54; PMID:12933588; http://dx.doi.org/10.1182/blood-2003-01-0291.
102. Hao SX, Ren R. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol 2000; 20:1149-61; PMID:10648600; http://dx.doi.org/10.1128/MCB.20.4.1149-1161.2000.
103. Schmidt M, Nagel S, Proba J, Thiede C, Ritter M, Waring JF, et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 1998; 91:22-9; PMID:9414265.
104. Schmidt M, Hochhaus A, itsche A, Hehlmann R, Neubauer A. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferonalpha. Blood 2001; 97:3648-50; PMID:11369663; http://dx.doi.org/10.1182/blood.V97.11.3648.
105. Ortmann CA, Burchert A, Hölzle K, Nitsche A, Wittig B, Neubauer A, et al. Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region. Nucleic Acids Res 2005; 33:6895-905; PMID:16396836; http://dx.doi.org/10.1093/nar/gki1001.
106. Schmidt M, Hochhaus A, König-Merediz SA, Brendel C, Proba J, Hoppe GJ, et al. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy. J Clin Oncol 2000; 18:3331-8; PMID:11013272.
107. Deng M, Daley GQ. Expressin of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. Blood 2001; 97:3491-7; PMID:11369642; http://dx.doi.org/10.1182/blood.V97.11.3491.
108. Tailor P, Tamura T, Kong HJ, Kubota T, Kubota M, Borghi P, et al. The feedback phase of Type I interferon induction in dendritic cells requires interferon regulatory factor 8. Immunity 2007; 27:228-39; PMID:17702615; http://dx.doi.org/10.1016/j.immuni.2007.06.009.
109. Hu X, Yang D, Zimmerman M, Liu F, Yang J, Kannan S, et al. IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. Cancer Res 2011; 71:2882-91; PMID:21487040; http://dxldoi.org/10.1158/0008-5472.CAN-10-2493.
110. Liu K, Abrams SI. Coordinate regulation of IFN consensus sequence-binding prtein and caspase-1 in the sensitization of human colon carcinoma cells to Fas-mediated apoptosis by IFN-γ. J Immunol 2003; 170:6329-37; PMID:12794166.
111. Huang W, Zhu C, Wang H, Horvath E, Eklund EA. The interferon consensus sequence-binding protein (ICSBP/IRF8) represses PTPN13 gene transcription in differentiating myeloid cells. J Biol Chem 2008; 283:7921-35; PMID:18195016; http://dx.doi.org/10.1074/jbc.M706710200.
112. Yang D, Thangaraju M, Greeneltch K, Browning DD, Schoenlein PV, Tamura T, et al. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenoType in metastatic tumor cells. Cancer Res 2007; 67:3301-9; PMID:17409439; http://dxldoi.org/10.1158/0008-5472.CAN-06-4068.
113. Lee KY, Geng H, Ng KM, Yu J, van Hasselt A, Cao Y, et al. Epigenetic disrupton of interferongamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. Oncogene 2008; 27:5267-76; PMID:18469857; http://dx.doi.org/10.1038/onc.2008.147.
114. Kessler DS, Veals SA, Fu XY, Levy DE. Interferonalpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes Dev 1990; 4:1753-65; PMID:2249773; http://dx.doi.org/10.1101/gad.4.10.1753.
115. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424:516-23; PMID:12872134; http://dxldoi.org/10.1038/nature01850.
116. Weihua X, Lindner DJ, Kalvakolanu DV. The interferon-inducible murie p48 (ISGF3γ) gene is regulated by protooncogene c-myc. Proc Natl Acad Sci U S A 1997; 94:7227-32; PMID:9207073; http://dx.doi.org/10.1073/pnas.94.14.7227.
117. DiPerna G, Stack J, Bowie AG, Boyd A, Kotwal G, Zhang Z, et al. Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem 2004; 279:36570-8; PMID:15215253; http://dx.doi.org/10.1074/jbc.M400567200.
118. Schröder M, Baran M, Bowie AG. Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J 2008; 27:2147-57; PMID:18636090; http://dxldoi.org/10.1038/emboj.2008.143.
119. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, et al. Immun evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005; 102:2992-7; PMID:15710891; http://dx.doi.org/10.1073/pnas.0408824102.
120. Seth RB, Sun L, Chen ZJ. Antiviral innate immunity pathways. Cell Res 2006; 16:141-7; PMID:16474426; http://dx.doi.org/10.1038/sj.cr.7310019.
121. Barro M, Patton JT. Rotavirus NSP1 inhibits expression of Type I interferon by antagonizing the function of interferon regulatory factors IRF3, IRF5, and IRF7. J Virol 2007; 81:4473-81; PMID:17301153; http://dxldoi.org/10.1128/JVI.02498-06.
122. Graff JW, Mitzel DN, Weisend CM, Flenniken ML, Hardy ME. Interferon egulatory factor 3 is a cellular partner of rotavirus NSP1. J Virol 2002; 76:9545-50; PMID:12186937; http://dx.doi.org/10.1128/JVI.76.18.9545-9550.2002.
123. Yu Y, Wang SE, Hayward GS. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosomemediated degradation. Immunity 2005; 22:59-70; PMID:15664159; http://dx.doi.org/10.1016/j.immuni.2004.11.011.
124. Offermann MK. Kaposi sarcoma herpesvirus-encoded interferon regulator factors. Curr Top Microbiol Immunol 2007; 312:185-209; PMID:17089798; http://dxldoi.org/10.1007/978-3-540-34344-8_7.
125. Burýsek L, Yeow WS, Lubyová B, Kellum M, Schafer SL, Huang YQ, et al. Functonal analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J Virol 1999; 73:7334-42; PMID:10438822.
126. Li M, Damania B, Alvarez X, Ogryzko V, Ozato K, Jung JU. Inhibition of p300 histone acetyltransferase by viral interferon regulatory factor. Mol Cell Biol 2000; 20:8254-63; PMID:11027294; http://dx.doi.org/10.1128/MCB.20.21.8254-8263.2000.
127. Burysek L, Yeow WS, Pitha PM. Unique properties of a second human herpesvirus 8-encoded interferon regulatory factor (vIRF-2). J Hum Virol 1999; 2:19-32; PMID:10200596.
128. Joo CH, Shin YC, Gack M, Wu L, Levy D, Jung JU. Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposi's sarcoma-associated herpesvirus viral IRF homolog vIRF3. J Virol 2007; 81:8282-92; PMID:17522209; http://dx.doi.org/10.1128/JVI.00235-07.
129. Wies E, Hahn AS, Schmidt K, Viebahn C, Rohland N, Lux A, et al. The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5. J Biol Chem 2009; 284:8525-38; PMID:19129183; http://dx.doi.org/10.1074/jbc.M809252200.
130. Pagano JS. Epstein-Barr virus: the first human tumor virus and its role in cancer. Proc Assoc Am Physicians 1999; 111:573-80; PMID:10591086; http://dxldoi.org/10.1046/j.1525-1381.1999.t01-1-99220.x.
131. Ning S, Campos AD, Darnay BG, Bentz GL, Pagano JS. TRAF6 and the three C-terminal lysie sites on IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor family member latent membrane protein 1. Mol Cell Biol 2008; 28:6536-46; PMID:18710948; http://dx.doi.org/10.1128/MCB.00785-08.
132. Song YJ, Izumi KM, Shinners NP, Gewurz BE, Kieff E. IRF7 activation by Epstein-Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3. Proc Natl Acad Sci U S A 2008; 105:18448-53; PMID:19017798; http://dx.doi.org/10.1073/pnas.0809933105.
133. Zhang L, Zhang J, Lambert Q, Der CJ, Del Valle L, Miklossy J, et al. Interferon regulatory factor 7 is associated with Epstein-Barr virus-transformed central nervous system lymphoma and has oncogenic properties. J Virol 2004; 78:12987-95; PMID:15542650; http://dxldoi.org/10.1128/JVI.78.23.12987-12995.2004.
134. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical applicatin. Nat Rev Cancer 2002; 2:342-50; PMID:12044010; http://dx.doi.org/10.1038/nrc798.
135. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 2000; 275:6764-9; PMID:10702232; http://dx.doi.org/10.1074/jbc.275.10.6764.
136. Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998; 12:2061-72; PMID:9649509; http://dxldoi.org/10.1101/gad.12.13.2061.
137. Venancio TM, DeMarco R, Almeida GT, Oliveira KC, Setubal JC, Verjovsi-Almeida S. Analysis of Schistosoma mansoni genes shared with Deuterostomia and with possible roles in host interactions. BMC Genomics 2007; 8:407; PMID:17996068; http://dx.doi.org/10.1186/1471-2164-8-407.
138. Nehyba J, Hrdlicková R, Bose HR. Dynamic evolution of immune system regulators: the history of the interferon regulatory factor family. Mol Biol Evol 2009; 26:2539-50; PMID:19638535; http://dx.doi.org/10.1093/molbev/msp167.
139. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κBB as the matchmaker. Nat Immunol 2011; 12:715-23; PMID:21772280; http://dx.doi.org/10.1038/ni.2060.